Researchers from the Cambridge Pancreatic Cancer Centre have identified a new pathway by which gemcitabine is broken down in tumour cells. The research is published in the British Journal of Cancer. Professor Duncan Jodrell, study author, said: “Gemcitabine is one of the drugs that we use commonly to treat pancreatic cancer, but the number of patients who benefit from it is still relatively small. Improving our understanding of how gemcitabine interacts with cellular metabolism may allow us to develop combination treatments that improve outcomes for patients with pancreatic cancer.” Details about the paper are on our publications page.